RenovoRx公司近日宣布,其用于通过血管滋养管(Vasa Vasorum)进行靶向局部给药的Renovocath®设备,已获得日本专利局发出的首份专利授权通知。这一进展标志着该公司在知识产权保护方面取得重要里程碑,为其创新药物输送技术在关键市场日本的商业化铺平道路。
RenovoRx公司近日宣布,其用于通过血管滋养管(Vasa Vasorum)进行靶向局部给药的Renovocath®设备,已获得日本专利局发出的首份专利授权通知。这一进展标志着该公司在知识产权保护方面取得重要里程碑,为其创新药物输送技术在关键市场日本的商业化铺平道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.